Memory Pharmaceuticals report positive preclinical data for 5-HT6 antagonist « GPCR News

Tags

5-HT1A 5-HT2 5-HT2A 5-HT3 5-HT4 5-ht6 5HT1A 5HT1D 5HT2 5HT2A 5HT3 5HT4 5ht6 agonist Angiotensin II AT1 antagonist Astrazeneca Beta 2 adrenoceptor Cannabinoid CB1 Daiichi-Sankyo Dopamine Dopamine D2 Fentanyl ghrelin GlaxoSmithkline GLP-1 gpcr GSK Histamine H1 Licensing Lilly Merck Muscarinic Opioid Opioid mu phase I phase II phase III Preclinical regulatory Research Sanofi-Aventis TRPV1 Vanilloid
August 2008

M T W T F S S

« Jul Sep »

1 2 3

4 5 6 7 8 9 10

11 12 13 14 15 16 17

18 19 20 21 22 23 24

25 26 27 28 29 30 31

Memory Pharmaceuticals report positive preclinical data for 5-HT6 antagonist

Posted on August 4, 2008 by crimsoncanary

Alzheimer’s Association International Conference show Memory Pharmaceutical’s 5-HT6 antagonist MEM 68626 to demonstate effecacy in animal models of cognition

Filed under: Uncategorized | Tagged: 5-ht6, 5ht6, antagonist, Memory, Preclinical

« Tracleer (bosentan) approved in EU for Pulmonary Arterial Hypertension Othera file IND for OT-730 in Glaucoma »

Leave a Reply